Tavazzi, GuidoRosselló, XavierGrand, JohannesGierlotka, MarekSionis, AlessandroAhrens, IngoHassager, ChristianPrice, Susanna2024-10-042024-10-042022-09-29Tavazzi G, Rossello X, Grand J, Gierlotka M, Sionis A, Ahrens I, et al. Epidemiology, monitoring, and treatment strategy in cardiogenic shock. A multinational cross-sectional survey of ESC-acute cardiovascular care association research section. Eur Hear Journal Acute Cardiovasc Care. 2022 Sep 29;11(9):706-11.http://hdl.handle.net/20.500.13003/18600https://hdl.handle.net/20.500.12105/23429This is a postprint (Accepted Manuscript) of an article published by Oxford in European Heart Journal. Acute Cardiovascular Care on 2022 September 29, available online: https://doi.org/10.1093/ehjacc/zuac087Aims: Cardiogenic shock (CS) is a life-threatening condition burdened by mortality in up to 50% of cases. Few recommendations exist with intermediate-low level of evidence on CS management and no data on adherence across centres exist. We performed a survey to frame CS management at multinational level. Methods and results: An international cross-sectional survey was created and approved by European Society of Cardiology-Acute Cardiovascular Care Association board. A total of 337 responses from 60 countries were obtained. Data were assessed by the hospital level of care of the participants. The most common cause of CS was AMI (AMI-CS-79.9%) with significant difference according to hospital levels (P = 0.001), followed by acutely decompensated heart failure (HF) (13.4%), myocarditis (3.5%), and de novo HF (1.75%). In 37.8%, percutaneous coronary intervention (PCI) is performed to all CS-patients as a standard approach, whereas 42.1% used PCI if electrocardiogram suggestive of ischaemia and 20.1% only if Universal definition of myocardial infarction criteria are fulfilled. Management (catecholamine titration and mechanical circulatory support escalation) is driven by mean arterial pressure (87.1%), echocardiography (84.4%), and lactate levels (83.4%). Combination of vasopressor and inotrope is chosen with the same frequency (37.7%) than inotrope alone as first-line pharmacological therapy (differences amongst hospital levels; P > 0.5). Noradrenaline is first-line vasopressor (89.9%) followed by dopamine (8.5%), whereas dobutamine is confirmed as the first-line inotrope (65.9%). Conclusion: Cardiogenic shock management is heterogenous and often not adherent to current recommendations. Quality improvement on an international level with evidence-based quality indicators should be developed to standardize diagnostic and therapeutic pathways.engSMURhttp://creativecommons.org/licenses/by-nc-nd/4.0/DobutamineTreatment OutcomeShock, CardiogenicHumansNorepinephrineDopamineCross-Sectional StudiesLactatesPercutaneous Coronary InterventionAttribution-NonCommercial-NoDerivatives 4.0 Internacional3594173011970610.1093/ehjacc/zuac0872048-8734European heart journal. Acute cardiovascular careopen accessNorepinefrinaDopaminaResultado del TratamientoEstudios TransversalesHumanosIntervención Coronaria PercutáneaDobutaminaLactatosChoque Cardiogénico837522700001L638690058